MA34380B1 - Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine - Google Patents

Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Info

Publication number
MA34380B1
MA34380B1 MA35567A MA35567A MA34380B1 MA 34380 B1 MA34380 B1 MA 34380B1 MA 35567 A MA35567 A MA 35567A MA 35567 A MA35567 A MA 35567A MA 34380 B1 MA34380 B1 MA 34380B1
Authority
MA
Morocco
Prior art keywords
derivative
ombrabulin
antitumor
association
platinum
Prior art date
Application number
MA35567A
Other languages
English (en)
Inventor
Patrick Cohen
Ileana Corina Oprea
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305653A external-priority patent/EP2397135A1/fr
Priority claimed from EP10306256A external-priority patent/EP2481404A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34380B1 publication Critical patent/MA34380B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platane et son utilisation dans le traitement de tumeurs solides développées.
MA35567A 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine MA34380B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305653A EP2397135A1 (fr) 2010-06-18 2010-06-18 Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
EP10306256A EP2481404A1 (fr) 2010-11-15 2010-11-15 Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
PCT/IB2011/052628 WO2011158206A1 (fr) 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Publications (1)

Publication Number Publication Date
MA34380B1 true MA34380B1 (fr) 2013-07-03

Family

ID=45347705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35567A MA34380B1 (fr) 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Country Status (23)

Country Link
US (1) US20130122113A1 (fr)
EP (1) EP2582369A1 (fr)
JP (1) JP2013528644A (fr)
KR (1) KR20130088753A (fr)
CN (1) CN103140224A (fr)
AR (1) AR082005A1 (fr)
AU (1) AU2011266635A1 (fr)
BR (1) BR112012031917A2 (fr)
CA (1) CA2802974A1 (fr)
CO (1) CO6650420A2 (fr)
DO (1) DOP2012000305A (fr)
EA (1) EA201291268A1 (fr)
EC (1) ECSP12012343A (fr)
MA (1) MA34380B1 (fr)
MX (1) MX2012014732A (fr)
NI (1) NI201200183A (fr)
PE (1) PE20130312A1 (fr)
PH (1) PH12012502483A1 (fr)
SG (1) SG186376A1 (fr)
TN (1) TN2012000552A1 (fr)
TW (1) TW201206419A (fr)
UY (1) UY33457A (fr)
WO (1) WO2011158206A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
KR100598474B1 (ko) 1998-04-03 2006-07-11 아지노모토 가부시키가이샤 항종양제
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
AR082005A1 (es) 2012-11-07
ECSP12012343A (es) 2012-12-28
TW201206419A (en) 2012-02-16
AU2011266635A1 (en) 2013-01-10
PE20130312A1 (es) 2013-03-26
KR20130088753A (ko) 2013-08-08
UY33457A (es) 2012-01-31
DOP2012000305A (es) 2013-01-31
US20130122113A1 (en) 2013-05-16
NI201200183A (es) 2013-05-13
CA2802974A1 (fr) 2011-12-22
BR112012031917A2 (pt) 2017-11-28
TN2012000552A1 (en) 2014-04-01
EA201291268A1 (ru) 2013-04-30
CN103140224A (zh) 2013-06-05
JP2013528644A (ja) 2013-07-11
EP2582369A1 (fr) 2013-04-24
SG186376A1 (en) 2013-01-30
WO2011158206A1 (fr) 2011-12-22
MX2012014732A (es) 2013-01-22
PH12012502483A1 (en) 2013-03-25
CO6650420A2 (es) 2013-04-15

Similar Documents

Publication Publication Date Title
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CY1118680T1 (el) Φαρμακευτικη συνθεση
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
MA42164A1 (fr) Composes biheteroaryle et leurs utilisations
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
CO6781549A2 (es) Uso de ligandos sigma en dolor por cáncer de huesos
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201590962A1 (ru) Новые соединения
IN2014DN09228A (fr)
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
EA201201623A1 (ru) Лечение диабета 2 типа
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
FR3063905B1 (fr) Utilisation de copaifera en cosmetique et en dermatologie